The Influence of Genetic Polymorphism on Dose- Dependent Analgesic Response and Safety to Propofol in General Anesthesia

This study investigates the influence of genetic polymorphisms in key drug-metabolizing enzymes-CYP2B6, CYP2C9, and UGT1A9-on the individual response to propofol, a widely used intravenous anesthetic, in patients undergoing general anesthesia. Despite propofol's fast onset and favorable recovery profile, significant inter-individual variability exists in its dosing requirements, sedation depth, and adverse effects. Such variability is believed to arise in part from genetic differences that affect drug metabolism and action. This research focuses on identifying how specific gene variants, particularly those linked to poor or altered metabolizer phenotypes, influence clinical outcomes like induction time, recovery time, and safety profiles during anesthesia.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Analgesia Agnosia Nervous System Diseases Neurobehavioral Manifestations Neurologic Manifestations Pathological Conditions, Signs and Symptoms Perceptual Disorders Signs and Symptoms

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Chaudary Muhammad Akram Teaching Hospital, Azra Naheed Medical College, Superior University

Lahore, Punjab Province, Pakistan

About this study

Focusing on the Pakistani population, this research seeks to fill a gap in regional pharmacogenetic data, which is limited but critical for optimizing patient care. By identifying associations between genetic profiles and anesthetic responses, the findings could support the development of personalized anesthesia protocols, improving drug safety and effectiveness. This project has great potential to advance precision medicine in anesthesiology by enabling more personalized therapeutic strategies that are guided by each patient's distinct genetic makeup.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Female & males aged 18-60yrs
ASA grade 1 & II
Patient enrolled for elective surgery
BM1 <35

Exclusion criteria

History of drug allergies
Any chronic disease such as hepatic, psychiatric & kidney disease.
History of drug intake (opioids, analgesics)
History of smoking, alcohol or drug addiction.

Treatment and study plan

Propofol Group

Diagnostic Test

Propofol will be administered according to the standard protocol, adjusted to each patient's condition and characteristics

Isoflurane Group

Combination Product

Isoflurane will be used as an inhalational aesthetic

Primary outcomes

Propofol therapeutic outcomes

Time frame: 24 Months

Produces prompt hypnosis (within 40 seconds) and allows for rapid awakening upon discontinuation (10-30 min)

Sponsors and collaborators

Lead sponsor

Superior University

Other

Registry information

Important dates

Study start: 2025
Primary completion: 2026
Study completion: 2027
First posted: Apr 22, 2026
Registry last updated: Apr 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Active, Not Recruiting